Facebook
X
LinkedIn
Forward2026 Endocrinology Grand Rounds | Adrenocortical Carcinoma Management Updates
Adrenocortical carcinoma is a deadly disease, which is rare and aggressive, and most clinicians do not feel comfortable managing it. Most clinicians are not very well familiar with the care for their patients with adrenocortical carcinoma, due to insufficient training. Also systemic therapy in adrenocortical carcinoma management has become more advanced and the complexity of this treatment requires more and ongoing training.
For many clinicians treating adrenocortical cancers, it is not clear when to use systemic therapy and what are choices there are. This activity will increase the knowledge of endocrinologist to better understand how to manage patients with adrenocortical carcinoma. It also emphasizes which image modalities, the genetic testing used for it and, which systemic therapy is more useful in this cancer, based on updated guidelines on the management of adrenocortical carcinoma.
Target Audience
Faculty and Staff of department of Diabetes, Endocrinology and Metabolism, and all other allied health care professionals interested in the subject matter.
Learning Objectives
- Identify patients that need systemic therapy.
- Integrate systemic therapy in the management of adrenocortical cancer.
- Distinguish different systemic therapies available.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Mouhammed Amir Habra, MD Chief, Section of Endocrine Neoplasia; Executive Chair, American Australian Adrenal Alliance (A5); The University of Texas MD Anderson Cancer Center
Presenter: Dr. Habra has indicated the following relevant financial relationships: On the Speakers Bureau for Recordati Rare Diseases (relationship has ended).
Dr. Habra will be discussing the off-label or investigational use of Cabozantinib, Lenvatinib, and Immunotherapy.
Planner: Pooja Manroa, MD has indicated that there are no relevant financial relationships with ineligible companies.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2026 Endocrinology Grand Rounds | Adrenocortical Carcinoma Management Updates for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance